,36 However, the independent clinical prognostic significance of CDKN2A/B homozygous deletion in IDH-wildtype glioblastoma may be important only in tumors with unmethylated MGMT promoters, where overall survival (OS) is slightly lower compared to tumors without CDKN2A/B homozygous deletion, but this difference is statistically significant (median OS of 14.7 months and 16.9 months), which is not observed in MGMT methylated tumors.37 This evidence concerns the gene CDKN2A and glioblastoma.